Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Peninsula Wealth LLC

Peninsula Wealth LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,786 shares of the biopharmaceutical company’s stock after selling 894 shares during the quarter. Gilead Sciences comprises approximately 0.7% of Peninsula Wealth LLC’s investment portfolio, making the stock its 23rd biggest holding. Peninsula Wealth LLC’s holdings in Gilead Sciences were worth $3,860,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in GILD. Norges Bank acquired a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $1,789,254,000. FMR LLC lifted its position in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the period. Pacer Advisors Inc. boosted its stake in Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock valued at $594,370,000 after purchasing an additional 5,653,075 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter valued at $207,340,000. Finally, Invesco Ltd. raised its position in Gilead Sciences by 12.9% in the fourth quarter. Invesco Ltd. now owns 11,277,915 shares of the biopharmaceutical company’s stock worth $1,041,741,000 after acquiring an additional 1,292,399 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $103.63 on Monday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $129.04 billion, a P/E ratio of 280.08, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The stock’s 50 day moving average price is $108.34 and its two-hundred day moving average price is $96.89.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 3.05%. Gilead Sciences’s dividend payout ratio is 854.05%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on GILD. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Wells Fargo & Company upped their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Finally, The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.